|
|||||
|
|
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population |
|
| Authors: | Wei Hong Kai Wang Yi-ping Zhang Jun-yan Kou Dan Hong Dan Su Wei-min Mao Xin-min Yu Fa-jun Xie Xiao-jian Wang |
| Institution: | 13376. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China 23376. Zhejiang Key Laboratory of the Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, 310022, China 33376. Department of Respiratory Medicine, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China 43376. Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, 310002, China 53376. Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, 310058, China |
| Abstract: | ObjectiveThe aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).MethodsA total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods.ResultsThe overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival.ConclusionsOur data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum. |
| Keywords: | Non-small cell lung cancer Single nucleotide polymorphism Methylenetetrahydrofolate reductase Gemcitabine Excision repair cross-complementation group 1 |
| 本文献已被 CNKI SpringerLink 等数据库收录！ | |